1. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors
- Author
-
Bramble, Matthew S, Hoff, Nicole, Gilchuk, Pavlo, Mukadi, Patrick, Lu, Kai, Doshi, Reena H, Steffen, Imke, Nicholson, Bradly P, Lipson, Allen, Vashist, Neerja, Sinai, Cyrus, Spencer, D’andre, Olinger, Garrard, Wemakoy, Emile Okitolonda, Illunga, Benoit Kebela, Pettitt, James, Logue, James, Marchand, Jonathan, Varughese, Justin, Bennett, Richard S, Jahrling, Peter, Cavet, Guy, Serafini, Tito, Saphire, Erica Ollmann, Vilain, Eric, Muyembe-Tamfum, Jean Jacques, Hensely, Lisa E, Simmons, Graham, Crowe, James E, and Rimoin, Anne W
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Vaccine Related ,Orphan Drug ,Rare Diseases ,Emerging Infectious Diseases ,Biodefense ,Infectious Diseases ,Immunization ,Good Health and Well Being ,Antibodies ,Monoclonal ,Antibodies ,Neutralizing ,Antibodies ,Viral ,Antibody Specificity ,Antigens ,Viral ,Democratic Republic of the Congo ,Ebolavirus ,Glycoproteins ,Hemorrhagic Fever ,Ebola ,Humans ,Lassa virus ,Marburgvirus ,Neutralization Tests ,Ebola ,DRC ,filovirus ,immune response ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Biological sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
One year after a Zaire ebolavirus (EBOV) outbreak occurred in the Boende Health Zone of the Democratic Republic of the Congo during 2014, we sought to determine the breadth of immune response against diverse filoviruses including EBOV, Bundibugyo (BDBV), Sudan (SUDV), and Marburg (MARV) viruses. After assessing the 15 survivors, 5 individuals demonstrated some degree of reactivity to multiple ebolavirus species and, in some instances, Marburg virus. All 5 of these survivors had immunoreactivity to EBOV glycoprotein (GP) and EBOV VP40, and 4 had reactivity to EBOV nucleoprotein (NP). Three of these survivors showed serologic responses to the 3 species of ebolavirus GPs tested (EBOV, BDBV, SUDV). All 5 samples also exhibited ability to neutralize EBOV using live virus, in a plaque reduction neutralization test. Remarkably, 3 of these EBOV survivors had plasma antibody responses to MARV GP. In pseudovirus neutralization assays, serum antibodies from a subset of these survivors also neutralized EBOV, BDBV, SUDV, and Taï Forest virus as well as MARV. Collectively, these findings suggest that some survivors of naturally acquired ebolavirus infection mount not only a pan-ebolavirus response, but also in less frequent cases, a pan-filovirus neutralizing response.
- Published
- 2018